Docket Number:10A-1041124
Inventor:Jyh-Yih Chen, Chen-Hung Ting
IP Status:US 10232013 B2、TW I602572
Abstract:
TP4 as a cationic antimicrobial peptide (CAP). TP4 selectively toxic to breast cancer cells, in particular triple-negative breast cancer cell. It also shows good therapeutic efficacy in different animal models, indicating TP4 could potentially be applied into the treatment of malignant breast cancers in human.The mechanism-of-action involved into FOSB induction.
Fields of Application:
- Treatment of malignant breast cancer.
- Treatment of triple-negative malignant breast cancer.
- Targeting to the cancer with negatively charged membrane.
- Substitution or in combination with conventional chemotherapy, such as anthracyclines or taxanes-based drugs.
- FOSB as a prognosis factor or therapeutic target.
Advantages when compared to the existing technologies:
- Conventional chemotherapeutic drugs toxic to both of healthy or cancerous cells and cause side effects that likely to affect whole body; whereas, TP4 shows minor toxicity to the normal cells but strong cytotoxicity to malignant breast cancer cells.
- Conventional chemotherapy easily causes multiple drug resistance of cancer cells but this is not identified when cancer cells treated with CAP.
- The charge of CAP is required for their anticancer activity. Known breast cancer lytic peptide, NRC03 and NRC07, bears three and seven positive charges, respectively. And that NRC07 showed better breast cancer cell killing activity. TP4, however, bears ten positive charges. A dose of 5 x10-6 M of TP4 is sufficient to kill ~50 of BC cells. The same dose shown in NRC03 and NRC07 peptides in BC killing experiments were less than 20and 40, respectively.
- No therapeutic target is available for triple negative breast cancer (TNBC). Previous studies have indicated that overexpressed FRA1 or PARP proteins are possible therapeutic candidates. Current approaches designed to treat TNBC were through the inhibition of these two proteins. Different form others, we observed FOSB overexpression showed dramatic death effects to the TNBC cells. Conventional chemotherapeutic anthracyclines also induced FOSB expression in TNBC cells, suggesting FOSB as a biomarker to the effective drug responses and could be a novel therapeutic target. Different from current approaches that to treat TNBC through FRA1 or PARP inhibitors, we propose to treat TNBC through a manner of FOSB induction.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
